Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Check back for update

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jan 19, 2021 4:16pm

131 Views

Post# 32329056

RE:RE:RE:RE:Check back for update

Spot the differences, there are many.
https://www.fiercebiotech.com/biotech/lilly-backed-terns-raises-87m-for-multi-front-assault-nash

SPCEO1 wrote: When you do a really bad deal, the results are clearly going to be very bad, at least in the short term. Both TH and the brokers had to know this was going to be the case - if not there are nt=ot as smart as I have given them credit for. Like Juniper said earlier, they likely have just steeled themselves for the well deserved criticism and hope time will heal those wounds.

Wino115 wrote: @Canadapiet --weren't you scheduled for a call with IR? How did it go?
SPCEO, you're getting there, day-by-day. Seems you are right though that there are definitely existing shareholders who are essentially throwing in the towel this week. I don't think either the bankers or management thought they'd see this, but they should have expected such.

They should have a book up for the B. Riley Oncology you'd think. Will be interesting to see how that goes and maybe the B Riley guys will ask about their thinking on recent deal. I see a squirm and a few "mindbogglings".....

qwerty22 wrote:
I'm sure it'll come out tomorrow for the presentation

scarlet1967 wrote: This is what the new investor see if they look for more insights into the company and THTX is not a phase1 cancer company only at preclinical stage?
Then we go and talk about how to handle the capital market, big institutional investors, reputable analysts etc etc.